MedTrace Logo

Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease

NCT00849316 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-11-02

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney disease under normal clinical practice conditions in India.

Conditions

Interventions

DRUG

insulin aspart

Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Ankit Pathak, MD · Novo Nordisk India Ltd

  • Ashok Moharana, MD · Novo Nordisk India Private Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-11-30
Completion
2009-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849316 on ClinicalTrials.gov